Hair regrowth laser FoLix™

thuliumtabletop

Overview
FoLix is a non-ablative fractional laser system using hair stimulation technology to provide a safe, effective and simple treatment for women and men. Designed as the first FDA-cleared fractional laser for hair loss treatment, FoLix targets dermal tissue to stimulate natural regenerative processes and improve scalp hair appearance.

Key benefits

• First FDA-cleared fractional laser for hair loss
• Proven results: clinical studies show increases in hair count, follicular units per cm2 and improved scalp hair appearance
• Natural and safe approach that leverages the body’s own healing processes (no chemicals)
• Simple, quick 30-minute procedure with minimal discomfort and no downtime

SYSTEM / Technology
FoLix™ Laser Technology uses a unique algorithm to ensure optimal irradiance and area coverage by homogeneous placement of the laser’s micro‑beams onto the tissue, maximizing operational efficiency, patient comfort and clinical outcomes. The system offers customized settings tailored to the treated area and patient tolerability. An intuitive user interface incorporates FDA‑cleared settings to enable efficient, consistent treatments.

Device features

• FoliCool™ Tip (Patent Pending) — enhanced safety and comfort via constant cooling; designed to separate hair for smooth treatment
• Targeted laser energy for dermal coagulation to activate natural healing processes
• Optimized energy delivery to boost blood flow, cytokine activity and hair follicle stimulation

TREATMENT
The treatment approach avoids chemicals, needles, anesthesia and surgery. Recommended protocol: 4–6 sessions every four weeks, with maintenance treatments 2–3 times per year to sustain and enhance results. Typical treatment time is approximately 30 minutes per session, with minimal discomfort and no required after‑care downtime.

Clinical evidence
Proven results reported in prospective and retrospective studies (over 120 participating patients in cited studies), showing increases in hair count and follicular units and improved scalp hair appearance at 1‑month and 3‑month follow ups compared to baseline. (Clinical study references cited on file.)

Indications, contraindications & risks

• Indication for use: improving the appearance of scalp hair in adult males and females with Fitzpatrick skin types I–IV who are seeking treatment for hair loss
• Contraindications: not suitable for patients with concurrent cancer, history of skin cancer, pre‑cancerous lesions at the treatment area, active infection, chronic fungal or bacterial disease, or chronic dermatological conditions of the scalp
• Potential risks and adverse effects: redness, swelling, scarring, damage to natural skin texture (e.g. blisters), fragile skin, burns, hair shedding, itching, pigmentation changes
• Availability: varies by region and subject to local regulatory approvals

Specifications

• Product name / commercial denomination: FoLix™
• Technology: non‑ablative fractional laser; micro‑beam delivery with homogenized coverage algorithm
• Cooling: FoliCool™ Tip (constant cooling) — patent pending
• Settings: customizable, FDA‑cleared settings available via intuitive user interface
• Treatment protocol: 4–6 sessions every 4 weeks; maintenance 2–3 times/year
• Treatment duration: approx. 30 minutes per session
• Indicated Fitzpatrick skin types: I to IV (adults)
• Primary therapeutic effect: dermal coagulation to stimulate blood flow, cytokine activity and hair follicle stimulation
• Safety considerations: contraindications and possible adverse events as listed above